The agreement allows Amyris to own and distribute the produced products under the collaboration.
Amyris and Antibioticos commenced test fermentation runs in January 2011, and, based on the successful outcome of those production runs, are proceeding with expanded production.
Amyris CEO John Melo said this agreement with Antibioticos should allow them to reach the target initial production levels and meet customer demand for their near-term product offerings.
Antibioticos CEO Pucci Di Benisichi said this agreement merges their experience and technical capacity with Amyris’s technology and processes, and forms another important step in the strategy of diversifying their business portfolio.